Approval Expanded for Breast Cancer Drug Tykerb

To include certain postmenopausal women who need hormone therapy

MONDAY, Feb. 1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy.

The new approval is for Tykerb's use in combination with a second anti-cancer drug, Femara (letrozole), the agency said in a news release.

Advertisement

Related Stories • U.S. Database of Breast Cancer Treatment May Be Inaccurate • Nearly 900,000 Fewer Cancer Deaths Since 1990: Report • FDA Approves Test That Spots Aggressive Breast Cancer Related Videos Tumor Detecting App: Medicine's Next Big Thing? Powerful Combo Reducing Lymphedema Fighting Breast Cancer on Your Lunch Break Related Slides Breast Cancer Breast Self-Exam

In women with HER2-positive breast cancer, those who received Tykerb and Femara more than doubled the time they lived without progression of their cancer, compared with those who received Femara alone (35 weeks versus 13 weeks), the FDA said.

Tykerb, first approved in 2007, is designed to block signals that tumor cells need to grow.

The drug is produced by GlaxoSmithKline.

More information

The FDA has more about this approval.

-- Scott Roberts